

Dati Personali



Cognome, Nome: Lauro, Davide, ID Ricercatore: Scopus Author ID Author ID: 7003497608

Nazionalità: Italiana; *Data di Nascita:* 1969

Indirizzo: Dipartimento di Medicina dei Sistemi, Università degli Studi di Roma “Tor Vergata”, via Montpellier n.1 – 00133 Roma, Italia.

email: d.lauro@med.uniroma2.it.

Dichiaro di avere esperienza in studi clinici di fase II e fase III condotti secondo la GCP (Good Clinical Practice).

Attuale Posizione

1) Professore di I Fascia, S.S.D. Endocrinologia (MED/13), Direttore della Scuola di Specializzazione in Endocrinologia e Malattie del Metabolismo, Dipartimento di Medicina dei Sistemi, Università degli Studi di Roma “Tor Vergata”; 2) Direttore della UOC di Endocrinologia, Diabetologia e Malattie del Metabolismo, Centro di Riferimento per il Diabete di Tipo 2, Fondazione Policlinico di Tor Vergata, Viale Oxford 81, 00133 Roma.

Educazione e Formazione

1994: Laureato in Medicina e Chirurgia con 110/110 e lode, Università degli Studi di Roma Tor Vergata”, Italia.

1994: Abilitato alla Professione di Medico e Chirurgo con il massimo dei voti.

1999: Specializzazione in Endocrinologia con 70/70 e lode, Università degli Studi di Roma “La Sapienza”, Italia.

1997- 1999: Visiting Fellow, alla Development Endocrinology Branch, National Institute of Child Health, del National Institute of Health, Bethesda, MD, USA.

1999- 2000: Visiting Fellow, alla Diabetes Branch, National Institute of Diabetes, Digestive and Kidney Diseases, del National Institute of Health, Bethesda, MD, USA.

Esperienza Didattica

2002- ad oggi: Insegnamento di Endocrinologia nella Laurea Triennale in Scienze Motorie.

2002 - ad oggi: Insegnamento di Endocrinologia nel Corso di Laurea Magistrale in Scienze e Tecniche dello Sport.

2003- ad oggi: Insegnamento di Endocrinologia nella Scuola di Specializzazione in Genetica Medica.

2005 – ad oggi: Insegnamento di Endocrinologia del Master di Primo Livello Personal Trainer: Basi Scientifiche e Metodologiche.

2005 - 2006: Direttore del Master di Primo Livello in Personal Trainer: Basi Scientifiche e Metodologiche.

2007- ad oggi: Insegnamento di Endocrinologia nel Corso di Laurea Magistrale in Laurea Magistrale in Scienze e Tecniche delle Attività Motorie Preventive ed Adattate.

2007- ad oggi: Insegnamento di Endocrinologia nella Scuola di Specializzazione in Medicina Interna.

2008- ad oggi: Insegnamento di Endocrinologia nella Scuola di Specializzazione in Ortopedia.

2009- 2011: Incarico di docenza nel Master di II livello in Diabetologia in collaborazione con l'Università degli Studi di Roma "La Sapienza", l'Università degli Studi di Roma "Tor Vergata" e l'Università degli Studi di Siena.

2006-2011 Dottorato di Ricerca "Fisiopatologia Sperimentale e Medicina Molecolare" Università degli Studi di Roma "Tor Vergata"

2011-ad oggi Componente del Consiglio dei Docenti del Master in "Medicina Sperimentale e dei Sistemi", Università degli Studi di Roma "Tor Vergata".

2011 -2013 Direttore della Scuola di Specializzazione in Medicina dello Sport Università degli Studi di Roma "La Sapienza".

2012 – ad oggi: Direttore del Master in Medicina Estetica, Università degli Studi di Roma "Tor Vergata".

2013 – ad oggi: Direttore del Master in Diabetologia, Università degli Studi di Roma "Tor Vergata".

2013 – ad oggi: Direttore della Scuola di Specializzazione in Endocrinologia e Malattie Metaboliche, Università degli Studi di Roma Tor Vergata. degli Studi di ROMA "Tor Vergata".

Esperienze Lavorative

1999- 2002: Professore Associato in Endocrinologia, Dipartimento di Medicina Interna, Facoltà di Medicina e Chirurgia, Università degli Studi di Roma Tor Vergata, Italia.

2000- 2003: Dirigente di I Livello, Unità di Endocrinologia, Ospedale Fatebenefratelli, Isola Tiberina, Roma, Italia.

2002–2006: Professore Associato in Endocrinologia, Dipartimento di Medicina Interna, Facoltà di Medicina e Chirurgia, Università degli Studi di Roma "Tor Vergata", Italia.

2003 – 2008: Dirigente di I Livello , UOC di Endocrinologia, Fondazione Policlinico di Tor Vergata, Roma, Italia.

2007 –2012: Professore di I Fascia in Scienze Tecniche Mediche e Applicate (MED/50), Dipartimento di Medicina Interna, Facoltà di Medicina e Chirurgia, Università degli Studi di Roma Tor Vergata, Italia.

2008 – ad oggi: Direttore del Centro di Riferimento per il Diabete di Tipo 2, Fondazione Policlinico di Tor Vergata, Roma.

2012 – ad oggi: Professore di I Fascia in Endocrinologia (MED/13), Dipartimento di Medicina dei Sistemi, Università degli Studi di Roma "Tor Vergata".

2012 – 2016: Presidente del Comitato Etico IRCCS San Raffaele Pisana, Roma Italia.

2013 – ad oggi: Direttore della UOC in Endocrinologia, Diabetologia e Malattie del Metabolismo, Fondazione Policlinico di Tor Vergata, Roma, Italia.

2013 – ad oggi: Direttore della Scuola di Specializzazione in Endocrinologia e Malattie del Metabolismo, Facoltà di Medicina e Chirurgia, Università degli Studi di Roma “Tor Vergata”, Italia.

2014 – ad oggi: Membro del Consiglio Direttivo della Società Italiana di Diabetologia.

Indicatori Bibliometrici

Autore di 137 pubblicazioni peer review indexate in pubemed.

Citazioni e report (da SCOPUS). H-index: 35, Totale I.F. ~ 600,54; Citazioni: 3.627 in 2892 documenti.

Aree di Ricerca

- Analisi del segnale dell'insulina e dell'insulino resistenza con metodiche in vitro ed in vivo.
- Studi sulla funzione endoteliale usando approcci sperimentali in vivo ed in vitro.
- Analisi del Proteoma e tecniche applicate allo studio del segnale dell'insulina e alla fisiopatologia del Diabete Mellito di Tipo 2 e delle sue complicanze croniche con particolare riferimento alla Steatosi Epatica non Alcoolica (NAFLD) e all' Aterosclerosi.
- Ontogenesi e Funzionalità della Cellula beta pancreatica.
- Ruolo degli enzimi antiossidanti Perossiredossine nella patologia del Diabete Mellito.
- Studi Clinici sull'insulino resistenza e sulla secrezione insulinica.

Fondi di Ricerca (Last 10 Years)

- 2005-2007 Chief of Scientific Unit of the Italian Ministry of Education, University and Research co financing grant for the research program 2005.
- 2006-2009 Italian Department of Health grant 2005 "Meccanismi di Danno e Rigenerazione della Beta Cellula Pancreatica".
- 2007–2009 Italian Department of Health grant, directed from the IRCCS- Monzino Milano, titled "Insulin Resistance and Coronary Disease: Insights into Inflammation, Thrombosis and Metabolic Syndrome".
- 2009-2011 Grant from FILAS 'Project Lazio Region–Italy' Industrial Research, medical device
- 2012-2014 Specific Programme “Cooperation”–Theme "Health" Call identifier: FP7-HEALTH-2011-two-stage Proposal No: 279171-2Acronym: MEDIGENE.
- 2013-2017 Research grant ASI (Italian Agency of Space) contract number: ASI No. 2013-084-R.0
- 2013-2015: National Coordinator of Education, University and Research (PRIN) 2011 grant "New Aspects of the Pathophysiology of Diabetes Mellitus and Potential Therapeutic Applications" Protocol 2010JS3PMZ.
- 2/2016 – 2/2018 Grant Fondazione Roma “Mechanism linking increased adiposity and metabolic dysfunction to premature aging and vascular damage: role of oxidative stress and gastric hormones”

Collaborazioni Internazionali

- Prof. Domenico Accili, MD, Director of the Columbia University Diabetes and Endocrinology Research Center in New York City; USA, for the generation and phenotypic characterization of murine models suitable for the study of Diabetes Mellitus
- Dr. Marcel Blot-Chabaud INSERM U608 Laboratoire d'immunologie et d'hématologie, Marseille, France, to evaluate the activation of cellular ionic channels in different experimental models.
- Dr. Florin Grigorescu CRBM, CNRS / INSERM, Montpellier, France. Genetic study in different ethnic groups to identify new genetic variants associated with the development of Type 2 Diabetes.

Revisore delle seguenti riviste

Acta Diabetologica, Journal of Cellular Physiology, JCEM, IJIPP, Atherosclerosis, Diabetes Research and Clinical Practice, Diabetologia, Journal of Cellular and Molecular Medicine, PlosOne, Sarcoidosis, Saudi Medical Journal.

Premi

2006: Scientific prize Pietro Angeletti “Impaired Glucose Tolerance in Mice with a Target Impairment of Insulin Action in Muscle and Adipose Tissue”

2004: Scientific Prize Pende for Medical Study III Edition ‘Fondazione Nuove Proposte Culturali Centro Studi Medici Alfonso Motulose’

2002: Scientific Prize ‘Roberto De Pirro’ for researchers under 35 years Italian Society of Diabetology.

1999: Travel Grant Winner of 1000\$ National Institute of Health, Bethesda,MD, USA

1998: Travel Grant Winner of 1000\$ National Institute of Health, Bethesda,MD, USA

PUBBLICAZIONI

1. Moretti C., Scaldaferrì L., Bisceglia S., Sforza V., Cerilli M., Frajese G., Mariani S., **Lauro D.** e Frajese G. Endocrinologia Molecolare “Stato dell’arte”. Clinica Ospedaliera 6:43-53, 1995
2. Andreoli M., Danese D., **Lauro D.**, Ruggeri R., Pontecorvi A. “Ormoni tiroidei ed osteoporosi” Reumatismo 48 (Suppl. N°3):35-40, 1996
3. Valensise H., Liu Y.Y., Federici M., **Lauro D.**, Dell’Anna D., Romanini C., Sesti G. “Increased expression of low-affinity insulin receptor isoform and insulin/insulin-like growth factor-I hybrid receptors in term placenta from insulin resistant women with gestational hypertension” Diabetologia 39:952-960, 1996 **I.F. 5.689**
4. Federici M., **Lauro D.**, Sesti G. “Diabete mellito non insulino-dipendente: aspetti clinici degli studi di biologia molecolare” Metabolismo Oggi 13: 39-50, 1996 **I.F. 2.013**
5. Federici M., Zucaro L., Porzio O., Massoud R., Borboni P., **Lauro D.**, Sesti G. “Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of non-insulin-dependent diabetes mellitus subjects” J. Clin. Invest. 98: 2887-2893, 1996 **I.F. 14.307**
6. Federici M, Porzio O, Zucaro L, Fusco A, Borboni P, **Lauro D**, Sesti G. “Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues” Mol. Cell. Endocrinol. 129, 121-126, 1997 **I.F. 2.637**
7. Magnaterra R, Porzio O, Piemonte F, Bertoli A, Sesti G, Lauro D, Marlier LN, Federici G, Borboni P “The effects of pregnancy steroids on adaptation of beta cells to pregnancy involve the pancreatic glucose sensor glucokinase”. J. Endocrinol. 155, 247-253, 1997 **I.F. 3.023**
8. Federici M, Porzio O, Zucaro L, Giovannone B, Borboni P, Marini MA, **Lauro D**, Sesti G. “Increased abundance of insulin/IGF-I hybrid receptors in adipose tissue from NIDDM patients” Mol. Cell. Endocrinol. 135, 41-47, 1997 **I.F. 2.637**
9. Federici M, **Lauro D**, D’Adamo M, Giovannone B, Porzio O, Mellozzi M, Tamburrano G, Sbraccia P, Sesti G. “Expression of insulin/IGF-I hybrid receptors is increased in skeletal muscle of patients with chronic primary hyperinsulinemia”. Diabetes 47: 87-92, 1998 **I.F. 8.298**.
10. Sesti G., **Lauro D.**, Federici M. “Prospettive terapeutiche del diabete mellito con fattori di crescita (IGF-I)” Metabolismo Oggi 15: 28-38, 1998 **I.F. 2.013**

11. Federici M, Porzio O, **Lauro D**, Borboni P, Giovannone B, Zucaro L, Hribal ML, Sesti G. “Increased abundance of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of obese subjects is correlated with in vivo insulin sensitivity” *J. Clin. Endocrinol. Metab.* 83: 2911-2915, 1998 **I.F. 5.799**
12. **Lauro D**, Kido Y, Castle AL, Zarnowski MJ, Hayashi H, Ebina Y, Accili D “Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue” *Nat. Genet.* 20, 294-298 1998 **I.F. 29.6**
13. Porzio O, Federici M, Hribal ML, **Lauro D**, Accili D, Lauro L, Patrizia Borboni, and Giorgio Sesti “The Gly⁹⁷² Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic β cells” *J. Clin. Invest.* 104:357–364, 1999 **I.F. 14.12**
14. Borboni P, Porzio O, Pierucci D, Cicconi S, Magnaterra R, Federici M, Sesti G, **Lauro D**, D'Agata V, Cavallaro S, Marlier LN “Molecular and functional characterization of pituitary adenylatecyclase-activating polypeptide (PACAP-38)/vasoactive intestinal polypeptide receptors in pancreatic beta-cells and effects of PACAP-38 on components of the insulin secretory system” *Endocrinology* 140:5530-7, 1999 **I.F. 4.971**
15. Porzio O, Marlier LN, Federici M, Hribal ML, Magnaterra R, **Lauro D**, Fusco A, Sesti G, Borboni P. “GLUT2 and glucokinase expression is coordinately regulated by sulfonylurea” *Mol Cell Endocrinol* 153: 155-61, 1999 **I.F. 2.637**
16. Federici M, Giaccari A, Hribal ML, Giovannone B, **Lauro D**, Morviducci L, Pastore L, Tamburrano G, Lauro R, Sesti G “Evidence for glucose/hexosamine in vivo regulation of insulin/IGF-I hybrid receptor assembly” *Diabetes* 48: 2277-85, 1999 **I.F. 8.3**
17. **Lauro D**, Kido Y, Hayashi H, Ebina Y, Accili D. “Expression of kinase-inactive mutant insulin receptors does not rescue insulin receptor-deficient mice from perinatal death”. *Diabetologia* 42, 1441-1442 1999 **I.F. 5.689**
18. Hribal ML, Federici M, Porzio O, **Lauro D**, Borboni P, Accili D, Lauro R, Sesti G. “The Gly \rightarrow Arg⁹⁷² amino acid polymorphism in IRS-1 affects glucose metabolism in skeletal muscle cells”. *J. Clin. Endocrinol. Metab.* 85: 2004-2013, 2000 **I.F. 5.799**
19. Federici M, Hribal ML, Ranalli M, Marselli L, Porzio O, **Lauro D**, Borboni P, Lauro R, Marchetti P, Melino G, Sesti G. “The common Arg⁹⁷² polymorphism in insulin receptor substrate-1 cause apoptosis of human pancreatic islets” *FASEB J.* 2001 Jan;15(1):22-24 **I.F. 7.172**
20. Giovannone B, Scaldaferrri ML, Federici M, Porzio O, **Lauro D**, Fusco A, Sbraccia P, Borboni P, Lauro R, Sesti G. “Insulin receptor substrate (IRS) transduction system:

- distinct and overlapping signaling potential” *Diabetes Metab Res Rev*. 2000 Nov-Dec;16(6):434-41. Review **I.F. 3.025**
21. Hribal ML, D'Alfonso R, Giovannone B, **Lauro D**, Liu YY, Borboni P, Federici M, Lauro R, Sesti G. “The Sulfonylurea Glimperide Regulates Intracellular Routing of the Insulin-Receptor Complexes through their Interaction with Specific Protein Kinase C Isoforms”. *Mol Pharmacol*. 2001 Feb;59(2):322-30 **I.F. 5.650**
 22. Sesti G, Federici M, Hribal ML, **Lauro D**, Sbraccia P, Lauro R. “Defects of the insulin receptor substrate (IRS) system in human metabolic disorders” *FASEB J* 2001 Oct;15(12):2099-111 **I.F. 7.172**
 23. Sesti G, Federici M, **Lauro D**, Sbraccia P, Lauro R. “Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms” *Diabetes Metab Res Rev* 2001 Sep-Oct;17(5):363-73 **I.F. 2.3**
 24. Accili D, Kido Y, Nakae J, **Lauro D**, Park BC. “Genetics of type 2 diabetes: insight from targeted mouse mutants” *Curr Mol Med* 2001 Mar;1(1):9-23 **I.F. 4.85**
 25. Bertoli A, Fusco A, Andreoli A, Magnani A, Tulli A, **Lauro D**, De Lorenzo A. “Effect of subclinical hypothyroidism and obesity on whole-body and regional bone mineral content” *Horm Res* 2002;57(3-4):79-84 **I.F. 1.591**
 26. Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, **Lauro D**, Sbraccia P, Spagnoli LG, Sesti G, Lauro R. “Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells” *Circulation* 2002 Jul 23;106(4):466-72 **I.F. 12.563**
 27. Sbraccia P, D'Adamo M, Leonetti F, Buongiorno A, Silecchia G, Basso MS, Tamburrano G, **Lauro D**, Federici M, Di Daniele N, Lauro R. “Relationship between plasma free fatty acids and uncoupling protein-3 gene expression in skeletal muscle of obese subjects: in vitro evidence of a causal link” *Clin Endocr (OXF)* 2002 Aug; 57(2):199-207 **I.F.2.767**
 28. Federici M, Petrone A, Porzio O, Bizzarri C, **Lauro D**, D'Alfonso R, Patera I, Cappa M, Nisticò L, Baroni M, Sesti G, di Mario U, Lauro R, Buzzetti R. “The Gly⁹⁷²→Arg IRS-1 Variant IS Associated With Type 1 Diabetes in Continental Italy” *Diabetes* 2003 March; 52: 887-890 **I.F. 8.3**
 29. D'Alfonso R, Marini MA, Frittitta L, Sorge R, Frontoni S, Porzio O, Mariani LM, **Lauro D**, Gambardella S, Trischitta V, Federici M, Lauro R, Sesti G. “Polymorphisms

- of the insulin receptor substrate-2 in patients with type 2 diabetes” J Clin Endocrinol Metab 2003 Jan;88(1):317-22 **I.F.5.799**
- 30.** Sesti G, Cardellini M, Marini MA, Frontoni S, D'Adamo M, Del Guerra S, **Lauro D**, De Nicolais P, Sbraccia P, Del Prato S, Gambardella S, Federici M, Marchetti P, Lauro R. “A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects” Diabetes 2003 May;52(5):1280-3 **I.F. 8.3**
- 31.** Hribal ML, Perego L, Lovari S, Andreozzi F, Menghini R, Perego C, Finzi G, Usellini L, Placidi C, Capella C, Guzzi V, **Lauro D**, Bertuzzi F, Davalli A, Pozza G, Pontiroli A, Federici M, Lauro R, Brunetti A, Folli F, Sesti G. “Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta cell line and human islets of Langerhans” FASEB J. 2003 Jul;17(10):1340-2 **I.F.7.172**
- 32.** Marini MA, Frontoni S, Mineo D, Bracaglia D, Cardellini M, De Nicolais P, Baroni A, D'Alfonso R, Perna M, **Lauro D**, Federici M, Gambardella S, Lauro R, Sesti G. “The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients“ J Clin Endocrinol Metab. 2003 Jul;88(7):3368-71 **I.F. 5.799**
- 33.** Federici M, Pandolfi A, De Filippis EA, Pellegrini G, Menghini R, **Lauro D**, Cardellini M, Romano M, Sesti G, Lauro R, Consoli A. “G972R IRS-1 Variant Impairs Insulin Regulation of Endothelial Nitric Oxide Synthase in Cultured Human Endothelial Cells“ Circulation. 2004 109(3):399-405 **I.F. 12.563**
- 34.** D'Alessandris C, Andreozzi F, Federici M, Cardellini M, Brunetti A, Ranalli M, Del Guerra S, **Lauro D**, Del Prato S, Marchetti P, Lauro R, Sesti G. “Increased O-glycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic beta-cells” FASEB J. 2004 Jun;18(9):959-61 **I.F. 7.172**
- 35.** Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, Irace C, **Lauro D**, Gnasso A, Federici M, Perticone F, Lauro R “The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.” Diabetes Care. 2004 Jun;27(6):1394-8. **I.F. 6.718**
- 36.** D'Adamo M, Perego L, Cardellini M, Marini MA, Frontoni S, Andreozzi F, Sciacqua A, **Lauro D**, Sbraccia P, Federici M, Paganelli M, Pontiroli AE, Lauro R, Perticone F,

- Folli F, Sesti G. "The -866A/A Genotype in the Promoter of the Human Uncoupling Protein 2 Gene Is Associated With Insulin Resistance and Increased Risk of Type 2 Diabetes." *Diabetes*. 2004 Jul;53(7):1905-1910. **I.F. 8.3**
37. Menghini R., Marchetti V., Cardellini M., Hribal M.L., Mauriello A., **Lauro D.**, Sbraccia P., Lauro R., Federici M. "Phosphorylation of GATA 2 by AKT Increases Adipose Tissue Differentiation and Reduces Adipose Tissue-Related Inflammation" *Circulation* 2005 111(15): 1946-1953 **I.F. 12.563**
38. Tesauro M., Schinzari F., Iantorno M., Rizza S., Melina D., **Lauro D.**, Cardillo C. "Ghrelin Improves Endothelial Function in Patients with Metabolic Syndrome " *Circulation* 2005 112(19): 2986-2992 **I.F. 12.563**
39. Federici M., Hribal M.L., Menghini R., Kanno H., Marchetti V., Porzio O., Sunnarborg S.W., Rizza S., Serino M., Cunsolo V., **Lauro D.**, Mauriello A., Smookler D.S., Sbraccia P., Sesti G., Lee D.C., Khokha R., Accili D., Lauro R. "Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha" *Journal Clin. Invest* 2005 115(12): 3494-505. **I.F. 14.307**
40. Rizza S., Tesauro M., Cardellini M., Menghini R., Bellia A., **Lauro D.**, Sbraccia P., Sesti G., Lauro R., Federici M. "Insulin Resistance and Increased Intimal Medial Thickness in Glucose Tolerant Offspring of Type 2 Diabetic Subjects Carrying the D298D Genotype of Endothelial Nitric Oxide Synthase" *Artherosclerosis, Thrombosis and Vascular Biology a Advanced* 2006 Feb;26(2):431-2. **I.F. 6.791**
41. Marchetti V., Menghini R, Rizza S, Vivanti A, Feccia T, **Lauro D.**, Fukamizu A, Lauro R, and Massimo Federici "Benfotiamine Counteracts Glucose Toxicity Effects on Endothelial Progenitor Cell Differentiation via Akt/FoxO Signaling" *Diabetes* 2006 55(8):2231-2237. **I.F. 8.3**
42. Cardellini M. , Marini M.A., Frontoni S., Hribal M.L., Andreozzi F., Perticone F., Federici M., **Lauro D.**, Sesti G. "Carotid artery intima-media thickness is associated with insulin-mediated glucose disposal in nondiabetic normotensive offspring of type 2 diabetic patients." *Am. J. Physiol. Endocrinol. Metab.* 2007 297 (1): E347-52. **I.F. 4.123**
43. Iantorno M., Chen H., Kim J.A., Tesauro M., **Lauro D.**, Cardillo C., Quon M.J. "Ghrelin Has Novel Vascular Actions That Mimic PI 3-Kinase-Dependent Actions of Insulin To Stimulate Production of No From Endothelial Cells" *Am. J. Physiol. Endocrinol. Metab.* 2007 292 (3): E756-64 **I.F. 4.123**

44. Tesauro M., Rizza S., Iantorno M., Campia U., **Lauro D.**, Leo R., Turriziani M., Cocciolillo G.C., Fusco A., Panza J.A., Scuteri A., Federici M., Lauro R., Quon M.J. “Vascular, Metabolic, and Inflammatory Abnormalities in Normoglycemic Offspring of Patients with Type 2 Diabetes Mellitus” *Metabolism* 2007, 56(3):413-419 **I.F.2.14**
45. Serino M., Menghini R., Fiorentino L., Amoruso R., Mauriello A., **Lauro D.**, Sbraccia P., Hribal M.L., Lauro R., Federici M. “Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes.” *Diabetes* 2007 (oct) 56(10):2541-6. **I.F. 8.3**
46. Scuteri A., Tesauro M., Rizza S., Iantorno M., Federici M, **Lauro D.**, Campia U., Turriziani M., Fusco A., Cocciolillo G., Lauro R. “Endothelial function and arterial stiffness in normotensive normoglycemic first-degree relatives of diabetic patients are independent of the metabolic syndrome” *Nutr. Met. Cardiovascular Disease* 2008 Jun;18(5):349-56. **I.F. 3.502**
47. Marchetti P., Dotta F. **Lauro D.**, Purrello F. “An overview of pancreatic beta-cell defects in human type 2 diabetes: Implications for treatment” *Regul Pep* 2008 Feb 7;146(1-3):4-11. **I.F. 2.387**
48. Hribal M., Torne I F., Pujol A., Menghini R., Barcaroli D., **Lauro D.**, Amoruso R., Lauro R., Bosch S., Sesti G., Federici M. “Transgenic mice overexpressing human G972R IRS-1 show impaired insulin action and insulin secretion.” *J. Cell. Mol. Med* 2008 Oct.;12(5B):2096-106. **I.F. 5.9.**
49. Tesauro M., Schinzari F., Rovella V., Melina D., Mores N., Barini A., Mettimano M., **Lauro D.**, Iantorno M., Quon M.J., Cardillo C. “TNF- α Antagonism Improves Vasodilation During Hyperinsulinemia in Metabolic Syndrome.” *Diabetes Care.* 2008 Jul;31(7):1439-41 **I.F. 6.718.**
50. A.Andreoli, **D. Lauro**, M. Celi, R. Sorge, U. Tarantino “37 Prevalence of Osteopenia and Osteoporosis in Italian Women Population” *Journal of Clinical Densitometry* 2009 January–March, Volume 12, Issue 1, Page 112-112.
51. Bellia A., Giardina E., **Lauro D.**, Tesauro M., Di Fede G., Cusumano G., Federici M., Rini G.B., Novelli G., Lauro R., Sbraccia P. "The Linosa Study": epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate” *Nutr Metab Cardiovasc Dis.* 2009 Sep;19(7):455-61. **I.F. 3.502**
52. Rizza S, Tesauro M, Cardillo C, Galli A, Iantorno M, Gigli F, Sbraccia P, Federici M, Quon MJ, **Lauro D.** “Fish oil supplementation improves endothelial function in

- normoglycemic offspring of patients with type 2 diabetes” *Atherosclerosis* 2009 Oct;206(2):569-74. **I.F. 4.150**
- 53.** Tesauro M, Schinzari F, Rovella V, Di Daniele N, **Lauro D**, Mores N, Veneziani A, Cardillo C. “Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome” *Hypertension* 2009 Nov;54(5):995-1000. **I.F. 6.908**
- 54.** Spitalieri P, Cortese G, Pietropolli A, Filareto A, Dolci S, Klinger FG, Giardina E, Di Cesare S, Bernardini L, **Lauro D**, Scaldaferrri ML, Citro G, Novelli G, De Felici M, Sangiuolo F. Identification of multipotent cytotrophoblast cells from human first trimester chorionic villi. *Cloning Stem Cells*. 2009 Dec;11(4):535-56. **I.F. 2.692**
- 55.** Rogliani P, Curradi G, Mura M, **Lauro D**, Federici M, Galli A, Saltini C, Cazzola M. “Metabolic syndrome and risk of pulmonary involvement” *Respir Med*. 2010 Jan;104(1):47-51. **I.F. 2.453**
- 56.** Folli F, Guzzi V, Perego L, Coletta DK, Finzi G, Placidi C, La Rosa S, Capella C, Succi C, **Lauro D**, Tripathy D, Jenkinson C, Paroni R, Orsenigo E, Cighetti G, Gregorini L, Staudacher C, Secchi A, Bachi A, Brownlee M, Fiorina P. “Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation” *PLoS One*. 2010 Mar 29;5(3):e9923. **I.F. 4.411. OK**
- 57.** Rizza S, Gigli F, Galli A, Michelini B, **Lauro D**, Lauro R, Federici M. “Adiponectin isoforms in elderly patients with or without coronary artery disease” *J Am Geriatr Soc*. 2010 Apr;58(4):702-6. **I.F. 3.913**
- 58.** Bellia A, Rizza S, Galli A, Fabiano R, Donadel G, Lombardo MF, Cardillo C, Sbraccia P, Tesauro M, **Lauro D**. “Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes” *Atherosclerosis*. 2010 May;210(1):199-201. **I.F. 4.150**
- 59.** Rizza S, Cardellini M, Martelli E, Porzio O, Pecchioli C, Nicolucci A, Marx N, Lauro D, Ippoliti A, Romeo F, Lauro R, Federici M. “Occult impaired glucose regulation in patients with atherosclerosis is associated to the number of affected vascular districts and inflammation.” *Atherosclerosis*. 2010 Sep;212(1):316-20. **I.F. 4.150**
- 60.** Schinzari F, Tesauro M, Rovella V, Galli A, Mores N, Porzio O, **Lauro D**, Cardillo C “Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients

- with obesity-related metabolic syndrome” *Am J Physiol Endocrinol Metab.* 2010 Dec;299(6):E947-52. 5. **I.F. 4.431**
61. Merlotti D, Gennari L, Dotta F, **Lauro D**, Nuti R. “Mechanisms of impaired bone strength in type 1 and 2 diabetes” *Nutr Metab Cardiovasc Dis.* 2010 Nov;20(9):683-9. **I.F. 3.502**
 62. Guglielmi V, D'Adamo M, D'Apice MR, Bellia A, **Lauro D**, Federici M, Lauro R, Novelli G, Sbraccia P. “Elbow deformities in a patient with mandibuloacral dysplasia type A” *Am J Med Genet A.* 2010 Nov;152A(11):2711-3. **I.F. 2.505**
 63. Rizza S, Cardellini M, Porzio O, Pecchioli C, Savo A, Cardolini I, Senese N, **Lauro D**, Sbraccia P, Lauro R, Federici M. “Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects” *Atherosclerosis.* 2011 Mar;215(1):180-3. **I.F. 4.15**
 64. Bacci S, Rizza S, Prudente S, Spoto B, Powers C, Facciorusso A, Pacilli A, **Lauro D**, Testa A, Zhang YY, Di Stolfo G, Mallamaci F, Tripepi G, Xu R, Mangiacotti D, Aucella F, Lauro R, Gervino EV, Hauser TH, Copetti M, De Cosmo S, Pellegrini F, Zoccali C, Federici M, Doria A, Trischitta V. “The ENPP1 Q121 Variant Predicts Major Cardiovascular Events in High-Risk Individuals: Evidence for Interaction With Obesity in Diabetic Patients” *Diabetes.* 2011 Mar;60(3):1000-7. **I. F. 8.3**
 65. Mammi C, Pastore D, Lombardo MF, Ferrelli F, Caprio M, Consoli C, Tesauro M, Gatta L, Fini M, Federici M, Sbraccia P, Donadel G, Bellia A, Rosano GM, Fabbri A, **Lauro D**. “Sildenafil reduces insulin-resistance in human endothelial cells” *PLoS One.* 2011 Jan 28;6(1):e14542. **I.F. 4.411**
 66. Rizza S, Muniyappa R, Iantorno M, Kim JA, Chen H, Pullikotil P, Senese N, Tesauro M, **Lauro D**, Cardillo C, Quon MJ. “Citrus Polyphenol Hesperidin Stimulates Production of Nitric Oxide in Endothelial Cells while Improving Endothelial Function and Reducing Inflammatory Markers in Patients with Metabolic Syndrome” *J Clin Endocrinol Metab.* 2011 May;96(5):E782-92. **I. F. 6.202**
 67. Tesauro M, Canale MP, Rodia G, Di Daniele N, **Lauro D**, Scuteri A, Cardillo C. “Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines” *Cardiol Res Pract.* 2011 Mar 7; 2011:653182
 68. Bellia A, Garcovich C, D'Adamo M, Lombardo M, Tesauro M, Donadel G, Gentileschi P, **Lauro D**, Federici M, Lauro R, Sbraccia P. “Serum 25-hydroxyvitamin D levels are

- inversely associated with systemic inflammation in severe obese subjects” Intern Emerg Med. 2011 Mar 25. [Epub ahead of print]. **I. F. 2.139**
- 69.** Andreoli A, Bazzocchi A, Celi M, **Lauro D**, Sorge R, Tarantino U, Guglielmi G. “Relationship between body composition, body mass index and bone mineral density in a large population of normal, osteopenic and osteoporotic women” Radiol Med. 2011 Jun 4. [Epub ahead of print]. **I. F. 1.618**
- 70.** Morviducci L, Di Flaviani A, Lauria A, Pitocco D, Pozzilli P, Suraci C, Frontoni S; **CSII Study Group Of Lazio Region, Italy**. “Continuous subcutaneous insulin infusion (CSII) in inpatient setting: unmet needs and the proposal of a CSII unit” Diabetes Technol Ther. 2011 Oct;13(10):1071-4. **I.F. 2.146**
- 71.** Lombardo MF, De Angelis F, Bova L, Bartolini B, Bertuzzi F, Nano R, Capuani B, Lauro R, Federici M, **Lauro D**, Donadel G. “Human placental lactogen (hPL-A) activates signaling pathways linked to cell survival and improves insulin secretion in human pancreatic islets.” Islets. 2011 Sep-Oct;3(5):250-8 **I.F. 1.487**
- 72.** Cardellini M, Menghini R, Luzi A, Davato F, Cardolini I, D'Alfonso R, Gentileschi P, Rizza S, Marini MA, Porzio O, **Lauro D**, Sbraccia P, Lauro R, Federici M. “Decreased IRS2 and TIMP3 Expression in Monocytes From Offspring of Type 2 Diabetic Patients Is Correlated With Insulin Resistance and Increased Intima-Media Thickness” Diabetes. 2011 Dec;60(12):3265-70. **I.F. 8.3**
- 73.** Casagrande V, Menghini R, Menini S, Marino A, Marchetti V, Cavalera M, Fabrizi M, Hribal ML, Pugliese G, Gentileschi P, Schillaci O, Porzio O, **Lauro D**, Sbraccia P, Lauro R, Federici M. “Overexpression of Tissue Inhibitor of Metalloproteinase 3 in Macrophages Reduces Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice” Arterioscler Thromb Vasc Biol. 2011 Oct 21. **I.F 7.235**
- 74.** Castaldo E, Sabato D, **Lauro D**, Sesti G, Marini MA. “Hypoglycemia assessed by continuous glucose monitoring is associated with preclinical atherosclerosis in individuals with impaired glucose tolerance” PLoS One. 2011;6(12):e28312. Epub 2011 Dec 2. **I.F. 4.411**
- 75.** Minella D, Wannenes F, Biancolella M, Amati F, Testa B, Nardone A, Bueno S, Fabbri A, **Lauro D**, Novelli G, Moretti C. “SOS1 over-expression in genital skin fibroblasts

- from hirsute women: a putative role of the SOS1/RAS pathway in the pathogenesis of hirsutism” *J Neurol Sci.* 2012 Apr 15;315(1-2):143-5. **I.F. 3.167**
- 76.** Menghini R, Casagrande V, Menini S, Marino A, Marzano V, Hribal ML, Gentileschi P, **Lauro D**, Schillaci O, Pugliese G, Sbraccia P, Urbani A, Lauro R, Federici M. “TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice” *Diabetes.* 2012 Feb;61(2):454-62. **I.F. 8.3**
- 77.** Cangemi R, Pignatelli P, Carnevale R, Nigro C, Proietti M, Angelico F, **Lauro D**, Basili S, Violi F. “Platelet Isoprostane Overproduction in Diabetic Patients Treated With Aspirin” *Diabetes.* 2012 Mar 16. **I.F. 8.3**
- 78.** Cazzola M, Calzetta L, Rogliani P, **Lauro D**, Novelli L, Page CP, Kanabar V, Matera MG. “High Glucose Enhances Responsiveness of Human Airways Smooth Muscle Via Rho/ROCK Pathway” *Am J Respir Cell Mol Biol.* 2012 May 31. **I.F. 5.125**
- 79.** Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield J, Ramachandran A, Riddle M, Rydén LE, Zinman B, Afzal R, Yusuf S, Gerstein H; TIDE Trial Investigators. “Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial” *Diabetologia.* 2012 Jan;55(1):36-45. **I.F. 05.689**
- 80.** Bellia A, Rizza S, Lombardo MF, Donadel G, Fabiano R, Andreadi K, Quon MJ, Sbraccia P, Federici M, Tesouro M, Cardillo C, **Lauro D**. “Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy” *Atherosclerosis.* 2012 Jul;223(1):197-203. **I.F. 4.150**
- 81.** Nisticò R, Cavallucci V, Piccinin S, Macri S, Pignatelli M, Mehdawy B, Blandini F, Laviola G, **Lauro D**, Mercuri NB, D'Amelio M. “Insulin Receptor β -Subunit Haploinsufficiency Impairs Hippocampal Late-Phase LTP and Recognition Memory.” *Neuromolecular Med.* 2012 Jun 3. **I.F. 5.0**
- 82.** Rizza S, Copetti M, Cardellini M, Porzio O, Luzi A, Pecchioli C, Martelli E, Valentini A, Ippoliti A, Romeo F, Pellegrini F, **Lauro D**, Lauro R, Federici M. “Atherosclerosis severity but not undiagnosed diabetes predicts new cardiovascular events of subjects in secondary cardiovascular prevention” *Atherosclerosis.* 2012 May 24. **I.F. 4.150**

83. Lombardo MF, Iacopino P, Cuzzola M, Spiniello E, Garreffa C, Ferrelli F, Coppola A, Saccardi R, Piaggese A, Piro R, Mannino D, Grossi G, **Lauro D**, Irrera G. "Type 2 diabetes mellitus impairs the maturation of endothelial progenitor cells and increases the number of circulating endothelial cells in peripheral blood" *Cytometry A*. 2012 Oct;81(10):856-64. **I.F. 3.729**
84. Bellia A, Marinoni G, D'Adamo M, Guglielmi V, Lombardo M, Donadel G, Gentileschi P, **Lauro D**, Federici M, Lauro R, Sbraccia P. "Parathyroid hormone and insulin resistance in distinct phenotypes of severe obesity: a cross-sectional analysis in middle-aged men and premenopausal women" *J Clin Endocrinol Metab*. 2012 Dec;97(12):4724-32. **I.F. 5.799**.
85. Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial) "Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial" *Nutr Metab Cardiovasc Dis*. 2012 Nov;22(11):997-1006. **I.F. 3.502**
86. Tesauro M, Schinzari F, Adamo A, Rovella V, Martini F, Mores N, Barini A, Pitocco D, Ghirlanda G, **Lauro D**, Campia U, Cardillo C. "Effects of GLP-1 on Forearm Vasodilator Function and Glucose Disposal During Hyperinsulinemia in the Metabolic Syndrome" *Diabetes Care*. 2013 Mar;36(3):683-9. **I.F. 8.1**
87. Fiorentino L, Cavalera M, Menini S, Marchetti V, Mavilio M, Fabrizi M, Conserva F, Casagrande V, Menghini R, Pontrelli P, Arisi I, D'Onofrio M, **Lauro D**, Khokha R, Accili D, Pugliese G, Gesualdo L, Lauro R, Federici M. "Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay" *EMBO Mol Med*. 2013 Mar;5(3):441-55. **I.F. 9.822**
88. Cazzola M, Calzetta L, **Lauro D**, Bettoncelli G, Cricelli C, Di Daniele N, Rogliani P. "Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit" *Respir Med*. 2013 May 20 S0954-6111(13)00171-6. **I.F. 2.659**
89. Urbani A, De Canio M, Palmieri F, Sechi S, Bini L, Castagnola M, Fasano M, Modesti A, Roncada P, Timperio AM, Bonizzi L, Brunori M, Cutruzzolà F, De Pinto V, Di Ilio

- C, Federici G, Folli F, Foti S, Gelfi C, **Lauro D**, Lucacchini A, Magni F, Messina I, Pandolfi PP, Papa S, Pucci P, Sacchetta P, The Italian Mt-Hpp Study Group-Italian Proteomics Association Www Itpa It. “The mitochondrial Italian Human Proteome Project initiative (mt-HPP)” *Mol Biosyst*. 2013 May 28. **I.F. 3.534**
- 90.** De Chiara V, Motta C, Rossi S, Studer V, Barbieri F, **Lauro D**, Bernardi G, Centonze D. “Interleukin-1 β alters the sensitivity of cannabinoid CB1 receptors controlling glutamate transmission in the striatum” *Neuroscience*. 2013 Oct 10;250:232-9. **I.F. 3.389**
- 91.** Scuteri A, Tesauro M, Guglini L, **Lauro D**, Fini M, Di Daniele N. “Aortic stiffness and hypotension episodes are associated with impaired cognitive function in older subjects with subjective complaints of memory loss” *Int J Cardiol*. 2013 Nov 20;169(5):371. **I.F. 4.125**
- 92.** Soresi M, Noto D, Cefalù AB, Martini S, Vigna GB, Fonda M, Manzato E, Cattin L, Fellin R, Averna MR, Notarbartolo A; Metabolic Syndrome Study Group. “Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society” *Acta Diabetol*. 2013 Apr;50(2):241-9. **I.F. 4.361**
- 93.** Bellia A, Sallì M, Lombardo M, D'Adamo M, Guglielmi V, Tirabasso C, Giordani L, Federici M, **Lauro D**, Foti C, Sbraccia P. “Effects of Whole Body Vibration Plus Diet on Insulin-Resistance in Middle-Aged Obese Subjects” *Int J Sports Med*. 2013 Nov 13. [Epub ahead of print]. **I.F. 2.268**
- 94.** Bellia A, Babini AC, Marchetto PE, Arsenio L, **Lauro D**, Lauro R. “Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy” . *Acta Diabetol*. 2014 Apr;51(2):269-75. **I.F. 4.631**
- 95.** Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, Caratelli S, Spagnoli GC, **Lauro D**, Lugli A, Han J, Iezzi G, Ferrone C, Ferlosio A, Tornillo L, Drosler R, Rossi P, Attanasio A, Ferrone S, Terracciano L. “HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker” *Neoplasia*. 2014 Jan;16(1):31-42. **I.F. 4.252**

- 96.** Giordani I, Di Flaviani A, Picconi F, Malandrucchio I, Ylli D, Palazzo P, Altavilla R, Vernieri F, Passarelli F, Donno S, **Lauro D**, Pasqualetti P, Frontoni S. Acute “Hyperglycemia Reduces Cerebrovascular Reactivity: The Role of Glycemic Variability” *J Clin Endocrinol Metab.* 2014 May 30. **I.F. 6.209**
- 97.** Pacifici F, Arriga R, Sorice GP, Capuani B, Scioli MG, Pastore D, Donadel G, Bellia A, Caratelli S, Coppola A, Ferrelli F, Federici M, Sconocchia G, Tesauro M, Sbraccia P, Della-Morte D, Giaccari A, Orlandi A, **Lauro D**. “Peroxiredoxin 6, a Novel Player in the Pathogenesis of Diabetes” *Diabetes.* 2014 Oct;63(10):3210-20. **I.F. 8.3**
- 98.** Della-Morte D, Palmirotta R, Rehni AK, Pastore D, Capuani B, Pacifici F, De Marchis ML, Dave KR, Bellia A, Fogliame G, Ferroni P, Donadel G, Cacciatore F, Abete P, Dong C, Pileggi A, Roselli M, Ricordi C, Sbraccia P, Guadagni F, Rundek T, **Lauro D** “Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors” *Pharmacogenomics.* 2014 Dec;15(16):2063-82. **I.F. 3.218**
- 99.** Della-Morte D, Riondino S, Ferroni P, Palmirotta R, Pastore D, **Lauro D**, Guadagni F, Roselli M. “Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity” *Pharmacogenomics.* 2015 Jan;16(1):61-78. **I.F. 3.218**
- 100.** Ferrelli F, Pastore D, Capuani B, Lombardo MF, Blot-Chabaud M, Coppola A, Basello K, Galli A, Donadel G, Romano M, Caratelli S, Pacifici F, Arriga R, Di Daniele N, Sbraccia P, Sconocchia G, Bellia A, Tesauro M, Federici M, Della-Morte D, **Lauro D**. “Serum glucocorticoid inducible kinase (SGK)-1 protects endothelial cells against oxidative stress and apoptosis induced by hyperglycaemia” *Acta Diabetol.* 2015 Feb; 52(1):55-64. **I.F. 4.631**
- 101.** Tesauro M, Nisticò S, Noce A, Tarantino A, Marrone G, Costa A, Rovella V, Di Cola G, Campia U, **Lauro D**, Cardillo C, Di Daniele N. “The possible role of glutathione-S-transferase activity in diabetic nephropathy” *Int J Immunopathol Pharmacol.* 2015 Mar;28(1):129-33. **I.F. 1.617**
- 102.** Aureli A, Canossi A, Del Beato T, Franceschilli L, Buonomo O, Papola F, De Sanctis F, Lanzilli G, Sileri P, Coppola A, Caratelli S, Arriga R, Orlandi A, **Lauro D**, Rossi P, Sconocchia G. “HLA-DRB1*13:01 allele in the genetic susceptibility to colorectal carcinoma” *Int J Cancer.* 2015 May 15;136(10):2464-8.

- 103.** Coppola A, Arriga R, **Lauro D**, Del Principe MI, Buccisano F, Maurillo L, Palomba P, Venditti A, Sconocchia G. “NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma” *Front Med (Lausanne)*. 2015 May 26;2:33.
- 104.** Capuani B, Della-Morte D, Donadel G, Caratelli S, Bova L, Pastore D, De Canio M, D'Aguanno S, Coppola A, Pacifici F, Arriga R, Bellia A, Ferrelli F, Tesauro M, Federici M, Neri A, Bernardini S, Sbraccia P, Di Daniele N, Sconocchia G, Orlandi A, Urbani A, **Lauro D**. “Liver protein profiles in insulin receptor-knockout mice reveal novel molecules involved in the diabetes pathophysiology” *Am J Physiol Endocrinol Metab*. 2015 May 1;308(9):E744-55. **I.F. 4.088**
- 105.** Maurizi AR, Suraci C, Pitocco D, Schiaffini R, Tubili C, Morviducci L, Giordano R, Manfrini S, **Lauro D**, Frontoni S, Pozzilli P, Buzzetti R; CSII Study Group of Lazio Region, Italy. “Position Statement on the management of continuous subcutaneous insulin infusion (CSII): the Italian experience” *J Diabetes*. 2015 Jun 29. **I.F. 1.932**
- 106.** Guglielmi V, D'Adamo M, Bellia A, Ciotto RT, Federici M, **Lauro D**, Sbraccia P. "Iron status in obesity: An independent association with metabolic parameters and effect of weight loss" *Nutr Metab Cardiovasc Dis*. 2015 Jun;25(6):541-7. **I.F. 3.323**
- 107.** Ciocca G, Carosa E, Stornelli M, Limoncin E, Gravina GL, Iannarelli R, Sperandio A, Di Sante S, Lenzi A, **Lauro D**, Jannini EA. “Post-traumatic stress disorder, coping strategies and type 2 diabetes: psychometric assessment after L'Aquila earthquake” *Acta Diabetol*. 2015 Jun;52(3):513-21. **I.F. 4.361**
- 108.** Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; **TECOS Study Group**. “Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes” *N Engl J Med*. 2015 Jul 16;373(3):232-42. **I.F. 54.42**
- 109.** Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Drosner R, Caratelli S, Ferrelli F, Coppola A, Arriga R, **Lauro D**, Iezzi G, Terracciano L, Ferrone S. “NK cells and T cells cooperate during the clinical course of colorectal cancer” *Oncoimmunology*. 2014 Aug 3;3(8):e952197. **I.F. 6.266**

110. **Lauro D**, Pastore D, Capuani B, Pacifici F, Palmirotta R, Abete P, Roselli M, Bellia A, Federici M, Di Daniele N, Sbraccia P, Guadagni F, Lauro R, Della-Morte D. “Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: a Novel Molecular Target against Age-Related Diseases” *Curr Med Chem*. 2015;22(33):3765-88.
111. Guglielmi V, Cardellini M, Cinti F, Corgosinho F, Cardolini I, D'Adamo M, Zingaretti MC, Bellia A, Lauro D, Gentileschi P, Federici M, Cinti S, Sbraccia P. “Omental adipose tissue fibrosis and insulin resistance in severe obesity” *Nutr Diabetes*. 2015 Aug 10;5:e175.
112. Basello K, Pacifici F, Capuani B, Pastore D, Lombardo M, Ferrelli F, Coppola A, Donadel G, Arriga R, Sconocchia G, Bellia A, Rogliani P, Federici M, Sbraccia P, **Lauro D**, Della-Morte D. “Serum- and Glucocorticoid-Inducible Kinase (SGK)1 delay the onset of Endothelial Senescence by Directly Interacting with hTERT” *Rejuvenation Res*. 2015 Jul 31.
113. Pastore D, Della-Morte D, Coppola A, Capuani B, Lombardo MF, Pacifici F, Ferrelli F, Arriga R, Mammi C, Federici M, Bellia A, Di Daniele N, Tesouro M, Donadel G, Noto D, Sbraccia P, Sconocchia G, **Lauro D**. “SGK-1 protects kidney cells against apoptosis induced by ceramide and TNF- α ” *Cell Death Dis*. 2015 Sep 17;6:e1890. doi: 10.1038/cddis.2015.232.
114. Vitale M, Masulli M, Rivellese AA, Babini AC, Boemi M, Bonora E, Buzzetti R, Ciano O, Cignarelli M, Cigolini M, Clemente G, Citro G, Corsi L, Dall'Aglio E, Del Prato S, Di Cianni G, Dolci MA, Giordano C, Iannarelli R, Iovine C, Lapolla A, **Lauro D**, Leotta S, Mazzucchelli C, Montani V, Perriello G, Romano G, Romeo F, Santarelli L, di Cola RS, Squatrito S, Tonutti L, Trevisan R, Turco AA, Zamboni C, Riccardi G, Vaccaro O. “Influence of dietary fat and carbohydrates proportions on plasma lipids, glucose control and low-grade inflammation in patients with type 2 diabetes-The TOSCA.IT Study” *Eur J Nutr*. 2016 Jun;55(4):1645-51.
115. Arriga R, Caratelli S, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lanzilli G, **Lauro D**, Palomba P, Sconocchia T, Del Principe MI, Maurillo L, Buccisano F, Capuani B, Ferrone S, Sconocchia G. “Enhancement of anti-leukemia activity of NK

- cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage. *Oncotarget*. 2016 Jan 12;7(2):2070-9.
116. D'Aloia MM, Caratelli S, Palumbo C, Battella S, Arriga R, **Lauro D**, Palmieri G, Sconocchia G, Alimandi M. "T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsionized target cells" *Cytotherapy*. 2016 Feb;18(2):278-90.
 117. Vancieri G, Bellia A, **Lauro D**. "Late-onset panhypopituitarism in a 72-year-old male patient treated with ipilimumab for metastatic melanoma: a case report" *J Endocrinol Invest*. 2016 Jul;39(7):805-6.
 118. Mascali A, Franzese O, Nisticò S, Campia U, **Lauro D**, Cardillo C, Di Daniele N, Tesauro M. "Obesity and kidney disease: Beyond the hyperfiltration" *Int J Immunopathol Pharmacol*. 2016 Sep;29(3):354-63.
 119. D'Amato C, Morganti R, Greco C, Di Gennaro F, Cacciotti L, Longo S, Mataluni G, **Lauro D**, Marfia GA, Spallone V. "Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities" *Diab Vasc Dis Res*. 2016 Nov;13(6):418-428.
 120. Palmirotta R, Cives M, Della-Morte D, Capuani B, **Lauro D**, Guadagni F, Silvestris F. "Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition" *Oxid Med Cell Longev*. 2016;2016:3031459
 121. Rogliani P, Calzetta L, Capuani B, Facciolo F, Cazzola M, **Lauro D**, Matera MG. Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. *Am J Respir Cell Mol Biol*. 2016 Dec;55(6):804-814.
 122. Capuani B, Pacifici F, Pastore D, Palmirotta R, Donadel G, Arriga R, Bellia A, Di Daniele N, Rogliani P, Abete P, Sbraccia P, Guadagni F, **Lauro D**, Della-Morte D. "The role of epsilon PKC in acute and chronic diseases: Possible pharmacological implications of its modulators." *Pharmacol Res*. 2016 Sep;111:659-67.
 123. Canossi A, Aureli A, Del Beato T, Rossi P, Franceschilli L, De Sanctis F, Sileri P, di Lorenzo N, Buonomo O, **Lauro D**, Venditti A, Sconocchia G. "Role of KIR and

- CD16A genotypes in colorectal carcinoma genetic risk and clinical stage. *J Transl Med.* 2016 Aug 12;14(1):239.
- 124.** Guglielmi V, Bellia A, Pecchioli S, Medea G, Parretti D, **Lauro D**, Sbraccia P, Federici M, Cricelli I, Cricelli C, Lapi F. “What is the actual epidemiology of familial hypercholesterolemia in Italy? Evidence from a National Primary Care Databas2. *Int J Cardiol.* 2016 Nov 15;223:701-705.
- 125.** De A, Pasquantonio G, Cerroni L, Petrelli D, **Lauro D**, Longhi M, Vitali LA. “Genotypic and phenotypic heterogeneity in *Streptococcus mutans* isolated from diabetic patients in Rome, Italy” *Springerplus.* 2016 Oct 13;5(1):1794. eCollection 2016.
- 126.** Vitale M, Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Nicolucci A, Squatrito S, Auciello S, Babini AC, Bani L, Buzzetti R, Cannarsa E, Cignarelli M, Cigolini M, Clemente G, Cocozza S, Corsi L, D'Angelo F, Dall'Aglio E, Di Cianni G, Fontana L, Gregori G, Grioni S, Giordano C, Iannarelli R, Iovine C, Lapolla A, **Lauro D**, Laviola L, Mazzucchelli C, Signorini S, Tonutti L, Trevisan R, Zamboni C, Riccardi G, Rivellese AA; TOSCA.IT Study Group. “Polyphenol intake and cardiovascular risk factors in a population with type 2 diabetes: The TOSCA.IT study” *Clin Nutr.* 2016 Nov 14. pii: S0261-5614(16)31316-4.
- 127.** Greco C, Di Gennaro F, D'Amato C, Morganti R, Corradini D, Sun A, Longo S, **Lauro D**, Pierangeli G, Cortelli P, Spallone V. Validation of the Composite Autonomic Symptom Score 31 (COMPASS 31) for the assessment of symptoms of autonomic neuropathy in people with diabetes. *Diabet Med.* 2016 Dec 19.
- 128.** Vitale M, Masulli M, Rivellese AA, Bonora E, Cappellini F, Nicolucci A, Squatrito S, Antenucci D, Barrea A, Bianchi C, Bianchini F, Fontana L, Fornengo P, Giorgino F, Gnasso A, Mannucci E, Mazzotti A, Nappo R, Palena AP, Pata P, Perriello G, Potenziani S, Radin R, Ricci L, Romeo F, Santini C, Scarponi M, Serra R, Timi A, Turco AA, Vedovato M, Zavaroni D, Grioni S, Riccardi G, Vaccaro O; TOSCA.IT Study Group. Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study. *Eur J Nutr.* 2016 Dec 2.
- 129.** Picconi F, Parravano M, Ylli D, Pasqualetti P, Coluzzi S, Giordani I, Malandrucchio I, **Lauro D**, Scarinci F, Giorno P, Varano M, Frontoni S. Retinal


neurodegeneration in patients with type 1 diabetes mellitus: the role of glyceimic variability. Acta Diabetol. 2017 Feb 25

Scopus (<http://www.scopus.com/authid/detail.url?authorId=7003497608>) Citations: 3627 total citations by 28926 documents; h-index: 35.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali (facoltativo)".

Roma 19/04/2017

Firma

A handwritten signature in black ink, appearing to read "Davide Lenzi". The signature is written in a cursive style with a long horizontal stroke at the end. It is positioned above a vertical line that extends downwards from the start of the signature.